- News Flash
10 October 2018
In a letter addressed to the hospital pharmacists, Bristol-Myers Squibb NV-SA has announced that it has decided to stop the commercialisation of Amukin (amikacin) and Maxipime (cefepime) as from January 1 2019 (reimbursement by RIZIV-INAMI will stop as from July 1 2019). For both antibiotics alternatives are available: Amikacine B. Braun and Cefepim Fresenius Kabi.
5 September 2018
Ketek (telithromycin) and Penstapho (oxacillin) are no longer available in Belgium. All referrals to these antibiotics have been removed from the IGGI documents.
1 May 2018
As from 1 May 2018 the reimbursement conditions for all pharmaceutical specialties containing an oral fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin, norflo-xacin and ofloxacin) has changed: reimbursement by RIZI-INAM in the outpatient practice will, as from this date, only be possible when certain conditions are met.
18 August 2017
In a letter addressed to the hospital pharmacists, Bristol-Myers Squibb NV-SA has announced that it has decided to stop the commercialisation of Pentrexyl (ampicillin) as from October 1 2017 (reimbursement by RIZIV-INAMI will stop as from April 1 2018). As there are no other (than Pentrexyl) formulations of ampicillin available in Belgium, the BSICM has decided to systematically replace ampicillin by amoxicillin (identical dosing) in all of its recommendations.
1 January 2016
Witboek over de machtiging tot verblijf om medische redenen (9ter).
Livre blanc sur l'autorisation de séjour pour des raisons médicales (9ter).
Under this title, a group of doctors, lawyers, field workers, ... published a White Paper in October 2015. The situation of seriously ill migrants is of great concern to them. The publication denounces the current application of medical regularisation.